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MicroRNAs (miRNAs) play an important role in various physiologic and developmental
processes and in the initiation and progression of cancer. This class of small, non-coding
RNAs critically regulate gene expression at the post-transcriptional level and evidence sug-
gests that they may function as both oncogenes and tumor suppressors. Colorectal cancer
(CRC) is a major healthcare concern worldwide and in order to reduce CRC related deaths,
research is aimed into the search for some novel screening approaches. In this sense, miR-
NAs are rapidly emerging as a novel class of biomarkers, with good potential as diagnostic
and therapeutic targets.This review summarizes the recent findings of the clinicopatholog-
ical relevance that miRNAs have in CRC initiation, development, and progress, highlighting
their potential diagnostic, prognostic, and therapeutic use in CRC, focusing on the group
of microsatellite instable and the group of hypermethylated CRCs, as well as discussing
future prospects.
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INTRODUCTION
Cancer is the leading cause of death in economically developed
countries and the second leading cause of death in develop-
ing countries. Colorectal cancer (CRC) is the third most com-
monly diagnosed cancer in males and the second in females, with
over 1.2 million new cases each year. CRC incidence rates are
rapidly increasing due to the effect of many risk factors, including
smoking, physical inactivity, excess weight and obesity, red and
processed meat consumption, and excessive alcohol consumption
(Jemal et al., 2011). CRC is a major health problem. In order to find
new diagnostic and therapeutic solutions that could help reduce
CRC related deaths, it is important to understand the etiologi-
cal and biological nature of CRC. Understanding the molecular
genesis of CRC is a fundamental step in the identification of
novel molecular targets that might be useful in defining the prog-
nosis of CRC patients and tailoring their therapy (Valeri et al.,
2009). Progression to CRC is considered a stepwise process, with
an accumulation of various genetic and epigenetic alterations,
leading to transformation from a normal cell to a premalignant
tumor and finally to a malignant and potentially metastatic tumor
(normal to adenoma to carcinoma sequence; Oberg et al., 2011).
CRC develops through two main genetic pathways, character-
ized by different forms of genomic instability, as presented in
Figure 1.
Most tumors (approximately 85%) are generated by the chro-
mosomal instability (CIN) pathway and display marked cyto-
genetic abnormalities, aneuploidy, and allelic losses at multiple
chromosomal arms. CIN is probably caused by various molec-
ular mechanisms but the underlying genetic alterations are still
poorly defined. This group is considered to be microsatellite sta-
ble (MSS). About 15% of colorectal carcinomas develop through
the microsatellite instability (MSI) pathway. MSI results from
defects in the DNA mismatch repair system (MMR). Molecularly
different subgroups of CRC tumors: MSS and MSI cancers histo-
logically appear similar but, clinically, they behave differently. MSI
adenocarcinomas display distinctive pathologic features, such as
proximal location, poor differentiation, frequent mucinous and
medullary phenotype, and marked peritumoral and intratumoral
lymphocytic infiltration. High microsatellite instable (MSI-H)
cancers have a better prognosis: in general, they follow a more
benign disease course; however, low MSI (MSI-L) cancers respond
less well to chemotherapy (Lanza et al., 2007; Schepeler et al.,
2008). MSI can occur through a germline mutation in MMR
genes or, in most sporadic cases, when the promoter region of
the genes in the MMR (usually MLH1) is silenced by hypermethy-
lation of the CpG island. Analysis of methylation of CpG islands,
as a mechanism of silencing genes in colon tumors, has resulted
in the identification of the CpG island methylator phenotype,
which seems to be complex and represents a third subclass of CRC
tumors. This serrated pathway, also called CpG island methylator
pathway (CIMP), usually occurs in the right colon, and seems to
be governed by a progression of different molecular mechanisms
to the classic adenoma carcinoma sequence (Cunningham et al.,
1998, 2010; Toyota et al., 1999; Shen et al., 2007).
Human cancers thus comprise both genetic (inherited and
acquired) and epigenetic alterations. Many tumor suppressor
genes and oncogenes have been described and the discovery of
new tumor markers continues at a rapid pace, also in CRC. A
novel group of biomarkers, microRNAs (miRNAs), has recently
been discovered. These molecules appear to be cell type and disease
specific, unlike most other markers currently available. MiRNAs,
as small regulatory non-coding RNA molecules, direct the bind-
ing of protein complexes to specific nucleic acid sequences and
can therefore repress the expression of the target genes at the
post-transcriptional level by interacting with the 3′ untranslated
regions (UTRs) of specific mRNAs (Fazi and Nervi, 2008). miR-
NAs are believed to have an impact on laboratory medicine as new
diagnostic and prognostic markers, as indicators of therapeutic
response, and as targets of novel therapies (Bartels and Tsongalis,
2009).
www.frontiersin.org October 2012 | Volume 3 | Article 180 | 1
Hrašovec and Glavacˇ MicroRNAs in colorectal cancer
FIGURE 1 | Genetic model of the adenoma to carcinoma sequence.
Chromosomal instability (CIN) and microsatellite instability (MSI) pathways,
with implicated third – CpG island methylator pathway (CIMP). Involved
miRNAs are indicated, together with assigned miRNA UP-(↑) or DOWN-(↓)
regulation. Modified from Slaby et al. (2009), Vilar et al. (2011), Valeri et al.
(2009), and Zarate et al. (2012).
In this review, we will focus on the critical role that miRNAs
have in CRC, summarize recent findings concerning the clinico-
pathological relevance and potential diagnostic, prognostic, and
therapeutic implications of miRNAs in CRC, briefly highlight
their potential as biomarkers in the group of microsatellite insta-
ble (MSI) and group of hypermethylated CRCs, as well as discuss
future prospects.
miRNA BIOGENESIS
At the time of this review, 1921 mature human miRNA
sequences were cataloged in the Sanger Institute miRBase (V18;
http://www.mirbase.org/index.shtml, accessed on 29 June 2012)
and over 6800 papers had been published in the PubMed
database associating miRNA to cancer, including 339 publications
concerning miRNA in CRC only.
MiRNAs are small, endogenous; single stranded RNA mole-
cules that play important regulatory roles in animals and plants
by targeting mRNAs for cleavage or translational repression of
approximately aq third of all known protein-coding genes. They
are transcribed as long primary transcripts – pri-miRNA, which
undergo sequential processing mediated by two RNase III endonu-
cleases, Drosha and Dicer. The process yields a ∼22-nucleotide
long duplex miRNA: miRNA∗. One strand of the duplex assembles
into the RNA interference-effector complex RISC (RNA-induced
silencing complex), whereas the other is generally degraded. The
complex is then directed to partially complementary miRNA
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Table 1 |Tumor suppressor miRNAs differentially expressed in colorectal cancer compared to normal mucosa and their predicted targets.
miRNA Expression status
in CRC (↑,↓)
Predicted
target gene
Reference
TUMOR SUPPRESSOR miRNAs
let-7 family ↓ KRAS Akao et al. (2006a), Torrisani et al. (2007), Han et al. (2012), Wang et al. (2011a), Earle
et al. (2010), Slattery et al. (2011)
miR-9 ↓ Lujambio et al. (2008), Bandres et al. (2009)
miR-16 ↓ Earle et al. (2010)
miR-26b ↓ Earle et al. (2010)
miR-34b/c ↓ C-MYC, E2F2, CDK6 Lujambio et al. (2008), Kalimutho et al. (2011), Toyota et al. (2008)
miR-129-2 ↓ Bandres et al. (2009)
miR-137 ↓ CDC42 Bandres et al. (2009)
miR-143 ↓ KRAS, DNMT3A, ERK5 Michael et al. (2003), Akao et al. (2006b), Slaby et al. (2007), Wang et al. (2009),
Motoyama et al. (2009), Chen et al. (2009), Earle et al. (2010), Ng et al. (2009)
miR-145 ↓ IRS-1, c-myc, SOX52 Michael et al. (2003), Akao et al. (2006b), Slaby et al. (2007), Wang et al. (2009),
Motoyama et al. (2009), Chen et al. (2009), Earle et al. (2010)
miR-148a ↓ TGIF2 Lujambio et al. (2008), Kalimutho et al. (2011)
miR-191 ↓ Earle et al. (2010)
miR-192 ↓ Earle et al. (2010), Balaguer et al. (2011)
miR-196a ↓ Earle et al. (2010)
mir-200c ↓ ZEB1, ZEB2 Chen et al. (2012a), Burk et al. (2008), Chen et al. (2012b)
miR-215 ↓ Earle et al. (2010), Slattery et al. (2011)
miR-342 ↓ DNMT1 Grady et al. (2008), Wang et al. (2011b)
miR-941 ↓ ADAM15 Yan et al. (2011)
miR-1247 ↓ Yan et al. (2011)
3′UTRs by base pairing (Bartel, 2004; Mirnezami et al., 2009). By
targeting mRNAs, they consequently inhibit mRNA translation
and protein synthesis or cause mRNA degradation, depending on
the imperfect pairing or exact match pairing to the mRNA, respec-
tively. In other words – whether translational inhibition or mRNA
degradation will occur depends on the degree of miRNA com-
plementarity to the mRNA molecule. For a functional interaction
between the miRNA and target sequence, only a limited num-
ber of complementary basepairs is required. The part of miRNA
that exactly aligns to mRNA is called “the seed sequence” and is
approximately 6–8 bases long (Bartels and Tsongalis, 2010). One
miRNA can target about 200 mRNAs responsible for various pro-
teins, while one mRNA can be controlled by several miRNAs (Lim
et al., 2005). In order to characterize the function of miRNA, it is
necessary properly to identify its target. The most commonly used
approach is a bioinformatical search using various computational
programs, such as TargetScan, miRanda, PicTar etc. (Lindow and
Gorodkin, 2007; Kuhn et al., 2008; Saito et al., 2009).
ALTERED miRNA EXPRESSION IN CANCER
Each miRNA can regulate hundreds of different protein-coding
genes. They have been shown to regulate several developmental
and basic cellular processes, such as cell differentiation, growth,
proliferation, and apoptosis. miRNA expression levels differ
between healthy tissue and cancerous tissue; moreover inhibi-
tion of Drosha or Dicer leads to decreased miRNA expression and
an enhancement of transformation and tumor growth (Williams,
2008). Over a decade ago,miRNAs were implicated in the initiation
of chronic lymphocytic leukemia. The authors for the first time
reported evidence of the involvement of miRNA genes in human
tumors (Calin et al., 2002). Lu et al. (2005) subsequently analyzed
the expression levels of more than 200 miRNAs across 334 primary
tumors, healthy tissue, and cell lines of a wide range of different
cancers and showed that the miRNA profile can better classify
tumors from control healthy samples than the mRNA expression
pattern. Since then, miRNAs have been shown to be involved in the
cancerogenesis of a variety of cancers, including CRC, with a role
as tumor suppressor genes or oncogenes (presented in Tables 1
and 2, respectively).
IMPORTANT TUMOR SUPPRESSOR AND ONCOGENIC
miRNAS AND THEIR CLINICOPATHOLOGICAL RELEVANCE IN
CRC
Different studies have used a variety of techniques to examine the
expression of selected miRNAs in order to determine their possi-
ble tumor suppressor or oncogenic function. Michael et al. (2003)
were the first to show that miR-143 and miR-145 consistently
display reduced steady-state levels of mature miRNA at the adeno-
matous and cancer stages of colorectal neoplasia, in comparison to
healthy colon mucosa. Another study found that miRNA-143 and
miRNA-145 expression levels were extremely reduced in colon
cancer cells and by transfecting each precursor miRNA into the
cells they achieved a significant growth inhibition in human colon
cancer DLD-1 and SW480 cells. They also determined ERK5 to be
the target gene of miRNA-143 (Akao et al., 2006b). Several other
researchers have confirmed those findings and correlated altered
miR-143 and miR-145 expression with clinicopathologic features
of CRC tumors. MiR-143 was found to be down-regulated in colon
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Table 2 | Oncogenic miRNAs differentially expressed in colorectal
cancer compared to normal mucosa and their predicted targets.
miRNA Expression
status in
CRC (↑,↓)
Predicted
target gene
Reference
miR-17-5p ↑ Lanza et al. (2007)
miR-20 ↑ Lanza et al. (2007), Earle et al.
(2010)
miR-21 ↑ PDCD4, MSH2,
MSH6, PTEN,
TPM1
Slaby et al. (2007), Asangani
et al. (2008), Schetter et al.
(2008), Link et al. (2010), Valeri
et al. (2010a), Slattery et al.
(2011)
miR-25 ↑ Lanza et al. (2007), Earle et al.
(2010)
miR-31 ↑ Earle et al. (2010)
miR-92-1 ↑ Lanza et al. (2007)
miR-92-5 ↑ Lanza et al. (2007)
miR-93-1 ↑ Lanza et al. (2007)
miR-106a ↑ Lanza et al. (2007)
miR-135a ↑ APC Earle et al. (2010)
miR-133b ↑ Earle et al. (2010)
miR-141 ↑ Cheng et al. (2011)
miR-155 ↑ MLH1, MSH2,
MSH6
Valeri et al. (2010b)
miR-183 ↑ Earle et al. (2010), Slattery
et al. (2011)
miR-200b ↑ De Roock et al. (2010)
miR-203 ↑ Earle et al. (2010)
miR-221 ↑ p53 Pu et al. (2010)
miR-223 ↑ Earle et al. (2010), Slattery
et al. (2011)
miR-320 ↑ Schepeler et al. (2008)
miR-498 ↑ Schepeler et al. (2008)
miR-622 ↑ Balaguer et al. (2011)
miR-1238 ↑ Balaguer et al. (2011)
but not in rectal cancer and miR-145 expression was related to the
cancer site. Researchers have shown that miR-143 functions as
a tumor suppressor through inhibition of KRAS translation and
that down-regulation of miR-143 drives tumor progression toward
malignancy (Slaby et al., 2007; Chen et al., 2009; Motoyama et al.,
2009; Wang et al., 2009). In the same study (Slaby et al., 2007), high
expression of miR-21 was for the first time associated with lymph
node positivity and the development of distant metastases in CRC.
They thus managed significantly to correlate miR-21 up-regulation
with CRC clinical stage (Slaby et al., 2007). Another group of
researchers investigated the contribution of miR-21 in tumor cell
invasion or intravasation. They confirmed for the first time an
inverse correlation between miR-21 and Pdcd4 protein expression
and proposed that miR-21 has a crucial role in post-transcriptional
down-regulation of tumor suppressor Pdcd4, whose function is to
stimulate cancer cell invasion, intravasation, and metastasis (Asan-
gani et al., 2008). High miR-21 expression in tumors was associated
with poor survival prognosis and poor therapeutic outcome in
CRC, and in adenoma tissue it was found significantly enriched:
1.6-fold higher than in healthy colon mucosa (Schetter et al., 2008).
Another group managed successfully to extract miRNA from stool
and found miR-21 expression to be higher in stool samples from
patients with colorectal neoplasia (adenocarcinomas and CRCs)
than with subjects with normal colonoscopies. They showed that
miRNAs could be easily, effectively, and reproducibly extracted
from freshly collected stools and proposed that fecal miRNAs could
serve as potential biomarkers in a non-invasive screening test for
colorectal neoplasm (Link et al., 2010).
One of the first discovered miRNA families was the let-7 fam-
ily and altered expression of these miRNAs has been described
in many cancers (Torrisani et al., 2007). A study by Akao et al.
showed reduced let-7 levels in CRC. When let-7 low-expressing
human CRC cells were transfected with let-7a-1 precursor miRNA,
this resulted in growth suppression and a decrease in RAS protein
levels. At the same time, the levels of mRNA remained almost
unchanged. Let-7 was suggested to act as a tumor suppressor in
CRC (Akao et al., 2006a). Several other authors have confirmed the
tumor growth suppression effect of let-7 family members, among
them let-7c, which influences MMP11 and PBX3 gene expression.
Let-7c was confirmed to have a tumor growth suppressor role
but also found to be a tumor metastasis suppressor, which directly
destabilizes the mRNA of MMP11 and PBX3 oncogenes (Han et al.,
2012). Another group reported the synthetic let-7a capacity sup-
press expression of oncogene NIRF and thus cause a reduction in
tumor growth. Their results open up the possibility of targeting
NIRF in CRC therapy (Wang et al., 2011a).
Another important family of miRNAs is the miR-200 family.
Members of this family, especially miR-200c, inhibit the metasta-
tic ability of cancer cells by targeting the transcriptional repressor
zinc-finger E-box binding homeobox 1 (ZEB1) in CRC. ZEB1 is a
crucial inducer of epithelial-mesenchimal transition, which pro-
motes malignant tumor progression, invasion, and metastasis of
tumor cells in various human cancers. Mir-200c was found to be
down-regulated in CRC and when over-expression was regained,
this significantly reduced the invasive potential of CRC cells (Burk
et al., 2008; Chen et al., 2012a). Another group investigated the
possible roles of miRNAs in regulating metastasis in paired CRC
cells. Their results showed that over-expression of miR-200c was
concurrent with down-regulation of ZEB1 mRNA and protein.
They demonstrated that miR-200c inhibits metastatic ability by
targeting ZEB1 in CRC cells and suggested that modulation of
miR-200c with inhibitors or mimics could serve as a therapeutic
tool for inhibiting metastasis in CRC. Their research provided a
new insight into the development of miRNA-based cancer gene
therapy for advanced CRC (Chen et al., 2012b).
miRNA AND MICROSATELLITE INSTABILITY
As shown in Figure 1, CRC develops through two main genetic
instability pathways, characterized by distinct pathologic features
and clinical outcome. A high level of MSI is the molecular hall-
mark of a subset of CRCs and miRNAs have been shown to be
useful in stratifying MSI-H CRCs from MSS CRCs. Lanza and col-
leagues evaluated miRNA expression in CRC samples and were the
first to report the existence of differences in miRNA expression
between MSS and MSI-H CRCs. Moreover, they suggested that
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the molecular classifier improves the separation between MSI and
MSS cancer samples and that a combination of mRNA/miRNA
expression signatures could provide improved stratification of
tumor-associated character. Their study revealed that miR-17-5p,
miR-20, miR-25, miR-92-1, miR-92-5, miR-93-1, and miR-106a
were significantly up-regulated in MSS tumors compared to MSI-
H. The above miRNAs are members of the mir-17-92 family,
organized in three gene clusters. The chromosomes 13 gene cluster,
which includes miR-17-92, had been previously found to be up-
regulated in B-cell lymphoma. All this data suggests that members
of miR-17-92 can act as oncogenes to promote cell growth and
inhibit apoptosis, so up-regulation of these miRNAs may have
a role in the more aggressive clinical behavior of MSS tumors
(He et al., 2005; Lanza et al., 2007). Schepeler’s group investi-
gated the expression profile of 315 human miRNAs in 10 normal
mucosa samples and 49 stage II CRC samples differing with regard
to microsatellite status and recurrence of disease. They showed
that the microsatellite status of the majority of samples could be
correctly predicted based on the miRNA expression profile. Fur-
thermore, a biomarker based on miRNA expression profiles could
predict recurrence of disease, indicating a potential role of miR-
NAs in determining tumor aggressiveness. The expression levels
of miR-320 and miR-498, both included in the predictive bio-
marker, correlated with the probability of recurrence-free survival.
In conclusion, they suggested that some miRNAs with prognostic
potential could be of clinical importance (Schepeler et al., 2008).
Another study showed that over-expression of miR-155 signif-
icantly down-regulates the core MMR proteins, hMSH2, hMSH6,
and hMLH1, inducing a mutator phenotype and MSI. They con-
firmed an inverse correlation between the expression of miR-155
and the expression of MLH1 or MSH2 proteins in CRC. In addi-
tion, a number of MSI tumors with unknown cause of MMR
inactivation displayed miR-155 over-expression. Their results pro-
vide support for miR-155 modulation of MMR as a mechanism
of cancer pathogenesis. This contributing role of miR-155 in the
down-regulation of the core MMR proteins suggests that miR-155
expression might become an additional analytic test for exploring
the etiology of MSI tumors when the standard tests do not pro-
vide a conclusive diagnosis (Valeri et al., 2010b). Another group
of researchers managed to associate miRNA expression in CRC
with MSI subgroups, including low MSI and hereditary non-
polyposis CRC (HNPCC – Lynch syndrome)-associated cancers.
They found 11 miRNAs (miR-183, -31, -20, -25, -92, -93, -17,
-135a, -203, -133b, and -223) to be over-expressed in CRC rela-
tive to mucosa and nine (miR-192, -215, -26b, -143, -145, -191,
-196a, -16, and let-7a) were under-expressed in CRC. The relative
expression of miR-92, -223, -155, -196a, -31, and -26b were signif-
icantly different among MSI subgroups, and miR-31 and miR-223
were over-expressed in CRC of patients with HNPCC (Earle et al.,
2010). Another group found eight miRNAs that appeared to be
uniquely differentially expressed in MSI-H tumors compared to
other tumor phenotypes, among others, miR-7, -183, -21, -215,
-223 (Slattery et al., 2011). Balaguer et al. developed a miRNA-
based predictor capable of differentiating between types of MSI
in an independent sample set, in order successfully to discrimi-
nate between Lynch syndrome, sporadic MSI and sporadic MSS
CRCs. They found a subset of nine miRNAs with deregulated
expression, with miR-622, miR-1238, and miR-192 having the
most differentially expressed expression between sporadic MSI
tumors and Lynch syndrome tumors (Balaguer et al., 2011).
MiR-21 over-expression in CRC has been reported several times,
as discussed above. However, Valeri et al. were able to provide
evidence that miR-21 directly targets the 3′UTR of MSH2 and
MSH6 mRNA. MiRNA over-expression dramatically reduces the
therapeutic efficacy of 5-FU via down-regulation of core mismatch
repair recognition protein complex hMSH2-hMSH6, causing both
primary and acquired resistance to 5-FU (Valeri et al., 2010a).
CIRCULATING PLASMA miRNAs IN CRC PATIENTS
Tumor-associated miRNAs have been detected in the serum or
plasma of patients suffering from breast and nasopharyngeal can-
cer, as well as CRC. Several studies have also reported that cell-free
circulating miRNAs exist in serum and plasma. Chen and col-
leagues showed that serum miRNAs are stable and that their levels
are reproducibly consistent among individuals of the same species.
They also demonstrated that the serum miRNA expression profile
can be used as a novel serum-based biomarker potentially offer-
ing more sensitive and specific tests than those currently available
for early diagnosis of cancer (Chen et al., 2008). Researchers have
confirmed miR-17-3p and miR-92 to be significantly elevated in
patients with CRC. They have also shown the plasma levels of
these markers to be significantly lower after surgical treatment.
Using a miRNA detection approach in serum, they were able to
discriminate CRC patients from control subjects with 89% sen-
sitivity and 70% specificity (Ng et al., 2008). Another group of
investigators proposed plasma miR-29a and miR-92a to be novel
biomarkers for early detection of CRC. In their study, they were
able to discriminate CRC patients from healthy controls by mea-
suring plasma levels of miR-29a and miR-92a. Furthermore, they
measured the expression of these miRNAs in plasma samples of
37 advanced adenomas, and found significantly elevated expres-
sion compared to those in normal controls. This study was one
of the first to evaluate the diagnostic value of plasma miRNas in
early detection of cancer (Huang et al., 2009). Pu and Huang et
al. investigated the availability of direct amplification of miRNAs
from plasma without RNA extraction. They revealed plasma lev-
els of miR-221 to be a potential biomarker for differentiating CRC
patients from controls. The elevated plasma miR-221 levels in their
study on 103 CRC patients were shown to be a significant prognos-
tic factor for poor overall survival and to be significantly correlated
to p53 expression. Direct amplification of plasma miR-221 was
therefore proposed as a potential non-invasive molecular marker
for diagnosis and prognosis of CRC (Pu et al., 2010). Another
group proposed miR-141 as a non-invasive biomarker in CRC.
The authors identified and validated circulating miR-141 to be
significantly associated with stage IV CRC in a large cohort of
CRC plasma samples. They found miR-141 to improve the carci-
noembryonic antigen role in detecting CRC patients with distant
metastasis, as well associated high levels of miR-141 in the plasma
of CRC patients with poor prognosis (Cheng et al., 2011). The
most recent publication relating to plasma miRNAs reported the
discovery of circulating miR-21 as a potential non-invasive marker
in CRC. They found miR-21 in their study to be more up-regulated
in stages III and IV than in stages I and II. Plasma miR-21 was able
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to differentiate CRC patients from controls with 90% specificity
and sensitivity (Kanaan et al., 2012).
miRNA AND HYPERMETHYLATION PROFILE
DNA methylation is an important epigenetic mechanism that
causes gene silencing. The so-called “CIMP pathway” has been
shown to be implicated in a substantial proportion of CRC cases
and has also been implicated in silencing of miRNA. Using the
miRNA expression profile and DNMT1/DNMT3b double knock-
out cell lines, researchers were able to show that DNA hyperme-
thylation contributes to the transcriptional down-regulation of
miRNA in CRC. They found that the expression of about 10%
of miRNAs was regulated by DNA methylation. In addition, nei-
ther 5-aza-2′deoxycytidine (5-Aza-CdR) treatment nor deletion
of DNMT1 alone restores the miRNA expression profile seen in
the double knockout cell line, suggesting that miRNA expression
was tightly controlled by DNA methylation and partial reduc-
tion was not efficient for miRNA re-expression (Han et al., 2007).
Moreover, with drug treatment of lymph node derived metastatic
cancer cells with a DNA demethylating agent, several miRNAs were
reactivated. Among them, miR-148a, miR-34b/c, and miR-9 were
found to undergo specific hypermethylation-associated silencing
in cancer cells compared to normal tissue. The consequence was
inhibited tumor cell motility, reduced tumor growth, and inhib-
ited metastasis formation, with an associated down-regulation of
miRNA oncogenic target genes, such as C-MYC, E2F2, CDK6, and
TGIF2. Their findings indicate that DNA methylation-associated
silencing of tumor suppressor miRNAs contributes to the devel-
opment of human cancer metastasis (Lujambio et al., 2008). In
addition, some other groups have investigated the hypermethyla-
tion of miR-34b/c in tumor DNA derived from feces and correlated
it with clinicopathological features. They explored whether miR-
34b/c could be used as a possible screening marker for the detection
of malignant cancer cells in feces as a novel non-invasive method.
They found that 75% (21/28) of samples had hypermethylated
miR-34b/c. They proposed miR-34b/c to be an ideal candidate
early screening marker in non-invasive fecal-DNA-based testing.
In addition, they also succeeded in correlating the epigenetic
silencing of miR-148a with a poor prognosis (Kalimutho et al.,
2011). Another group investigated miR-34b and miR-34c as two
components of the p53 network. Methylation of these two miR-
NAs was present in all cell lines investigated and in 90% (101/110)
of primary CRC tumors inspected, but not in normal colonic
mucosa. They found miRNA-34b and miR-34c to be epigeneti-
cally silenced in CRC. Their results also showed that transfection of
precursor miR-34b and miR-34c into CRC cells induced dramatic
changes in the gene expression profile. They found the miR-34b/c
CpG island to be a bidirectional promoter driving expression
of miR-34b/c genes and, due to the high frequency and tumor-
specificity of miR-34b/c methylation, they proposed that it could
serve as a useful tumor marker and important target in anticancer
therapy (Toyota et al., 2008).
Grady and collaborators found that the expression of miR-342,
a miRNA encoded in an intron of the EVL gene, was commonly
suppressed in CRC. They found methylation at the EVL/miR-342
locus to be present in the majority of CRCs and even in more than
half of adenomas, indicating that CpG island methylation of the
upstream region of EVL is an early event in colorectal carcino-
genesis. Furthermore, reconstitution of hsa-miR-342 in the CRC
cell line HT-29 induced apoptosis, suggesting that this miRNA
could function as a proapoptotic tumor suppressor. These results
show that epigenetic alterations of host genes could be a mech-
anism of silencing intronic miRNA (Grady et al., 2008). One of
the first miRNAs reported to be involved in CRC tumorigenesis
was miR-143. A later study elucidated a tumor-suppressive role
of miR-143 in the epigenetic aberration of CRC. The authors
defined DNMT3A as a potential target of miR-143 and there-
fore proposed miR-143 as a regulator of DNMT3A expression
in CRC. Restoration of miR-143 expression in colon cell lines
decreased tumor cell growth and soft-agar colony formation, and
down-regulated DNMT3A expression on both mRNA and protein
levels (Ng et al., 2009). Bandres and colleagues used a sequential
approach to identify tumor suppressor miRNAs that are silenced
through aberrant epigenetic events in CRC. They first searched
for down-regulated miRNAs that are located around/on a CpG
island. They then treated cell lines with DNA methyltranspherase
inhibitor in order to restore miRNA expression, and afterward
checked for methylated promoter regions in the investigated genes.
Using this approach, they identified down-regulation of miR-9-1,
miR-129-2, and miR-137 and their expression was found to be
in inverse correlation with their methylated promoter. Further-
more, methylation of miR-9-1 was associated with the presence
of lymph node metastasis. Their experiment demonstrated that
aberrant DNA methylation induces silencing of miRNA (Bandres
et al., 2009). Another group investigated the expression of miR-342
in CRC in correlation with over-expressed DNMT1. They showed
that miR-342 was down-regulated in CRC tissues and cell lines and
that restoration of miR-342 resulted in a dramatic reduction of the
expression of DNMT1 at both messenger RNA and protein levels,
by directly targeting its 3′UTR. This in turn reactivated ADAM23,
Hint1, RASSF1A, and RECK genes via promoter demethylation.
They proposed a new mechanism for the regulation of DNMT1
and aberrant DNA hypermethylation in CRC, as well as demon-
strating that miR-342 may act as a tumor suppressor gene in CRC
development (Wang et al., 2011b). A recent study systematically
searched for candidate miRNAs regulated by DNA methylation in
CRC cell lines. They established a comprehensive catalog consist-
ing of 64 epigenetically regulated miRNAs, of which 18 were shown
to have an expression level consistent with their methylation status.
Finally, the same authors performed a functional study to discover
whether miR-941 and miR-1247 have an impact on cell growth
and migration in CRC cell lines. They provided a reliable, system-
atic strategy for identifying new epigenetically regulated miRNAs
involved in CRC progression (Yan et al., 2011).
miRNA AND KRAS
miRNA post-transcriptional inhibition depends on sequence
complementation to 3′UTR of mRNA. Mutations in this region
could interfere with miRNA inhibition and if these mutations
occur in oncogenes, they may affect the important mechanism
of inhibition in tumor cells. KRAS is a member of the Ras fam-
ily of proteins, which regulates signaling pathways involved in
cellular proliferation, differentiation, and survival. Bandres et al.
searched for miRNA de-regulation patterns in patients carrying
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KRAS mutations and found that CRC cell lines with KRAS muta-
tions showed over-expression of miR-9, miR-95, miR-148a, miR-
190, and miR-372 in relation to the human normal colon cell
line. The same study reported lower over-expression of the same
miRNAs in CRC cell lines with mutations in BRAF. Activat-
ing mutations in BRAF are also considered able to activate the
RAS/RAF/MEK/ERK pathway, consequently increasing cell prolif-
eration but suppressing the inhibition of apoptosis. The authors
summarize that altered miRNA expression of some miRNAs may
deregulate cancer-related genes, such as KRAS and BRAF (Bandrés
et al., 2006). Chen and colleagues noted an inverse correlation in
KRAS protein levels in relation to miR-143 expression and a pos-
sible role of miRNAs in a tumor suppressor effect. They succeeded
in experimentally validating KRAS as an miR-143 target, since in
in vitro experiments, miR-143 directly bound to 3′UTR of the
KRAS transcript (Chen et al., 2009).
In the most recent paper, the authors provided evidence that an
increased level of miR-200b in KRAS mutated tumors is associated
with good progression free survival. Patients with an activating
mutation in KRAS were considered to be resistant to anti-EGFR
therapy. They suggested that a codon 13 KRAS mutation has
distinct clinical behavior and is not associated with anti-EGFR
resistance (De Roock et al., 2010). Another recently published
study proposed that elevated expression of miR-200b may be use-
ful for identifying patients with mutated KRAS who would benefit
from anti-EGFR therapy (Mekenkamp et al., 2012).
CONCLUSION AND FUTURE PROSPECTS
Since the first miRNA was identified in 1993, researchers have
aimed for better understanding of the miRNA function in mam-
mals. MiRNAs are easier and more appropriate to handle than
mRNA, which gives them potential value in patient management.
They clearly have a major impact on the initiation and CRC pro-
gression but in order to use them as diagnostic, prognostic, or
even therapeutic targets, it is essential to establish and validate
reliable, accurate, and standardized assays for the detection of aber-
rant miRNA expression. Secondly, when a therapeutic approach
considered, overcoming the problem of administering the thera-
peutic to a target cell, avoiding contamination of other cells and
organs, in order to minimize side effects, will be quite challeng-
ing. Although there are many obstacles to overcome, miRNAs
have great future prospects as tumor markers in cancer classi-
fication, early detection, prognosis prediction, and therapeutic
decision-making.
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